SPDYE3, A Novel Cancer Testis (CT) Antigen for Glioma Immunotherapy

项目总结 胶质瘤是一种具有恶性增殖能力的异质性脑瘤，没有治疗方法。 选择是治标的。我们的研究表明，一种不具特征的癌症睾丸抗原SPDYE3被发现 在所有亚型以及低级别和高级别胶质瘤中均过表达，其表达与 可怜的病人的生存。有趣的是，SPDYE3蛋白含有串联重复(Tr)表位，具有高 与主要的人类白细胞抗原单倍型(人类白细胞抗原-A*02、人类白细胞抗原-A*01和人类白细胞抗原-B*07)的结合亲和力，这使得 分子是基于TCR的T细胞治疗的潜在胶质瘤靶点。 在这项拟议的研究中，我们将检验我们的假设，即SPDYE3是一种新的胶质瘤肿瘤抗原， 它与肿瘤的进展有关。我们期待着将我们的临床前发现转化为 建议对未来不同阶段胶质瘤患者的临床应用进行研究。

PROJECT SUMMARY Gliomas are heterogeneous brain tumors with capacity for malignant propagation, and no treatment options are curative. Our studies show that an uncharacteristic cancer testis antigen, SPDYE3 was found to be overexpressed in all subtypes as well as low- and high-grade gliomas, and its expression is associated a poor patient’s survival. Interestingly, SPDYE3 protein contains tandem repeat (TR) epitopes that have high binding affinity to predominant HLA haplotypes (HLA-A*02, HLA-A*01 and HLA-B*07), which makes this molecule a potential glioma target for TCR-based T cell therapy. In this proposed study, we will test our hypothesis that SPDYE3 is a novel glioma tumor antigen, which is involved in tumor progression. We anticipate translating our preclinical findings from this proposed study into a future clinical applications for patients with various stages of gliomas.